￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Dacomitinib/Dacomitinib: a new treatment option for patients with EGFR mutation-positive non-small cell lung cancer

2026-02-01 22:25:32

Check Details
Discussion on the ideal medication period of dacomitinib/dacomitinib

2026-02-01 22:25:32

Check Details
Detailed explanation of dacomitinib/dacomitinib dosage forms and dosages

2026-02-01 22:25:32

Check Details
Potential effects of dacomitinib/dacomitinib on the cardiovascular system

2026-02-01 22:25:32

Check Details
Significant effect of dacomitinib/dacomitinib in the treatment of EGFR mutant non-small cell lung cancer

2026-02-01 22:25:32

Check Details
Dacomitinib/Dacomitinib which company is from

2026-02-01 22:25:32

Check Details
Is it effective to take 15 mg of dacomitinib/dacomitinib a day?

2026-02-01 22:25:32

Check Details
Can dacomitinib/dacomitinib and osimertinib be taken together?

2026-02-01 22:25:32

Check Details
The difference between dacomitinib and dacomitinib

2026-02-01 22:25:32

Check Details
Revealing the manufacturer of dacomitinib/dacomitinib

2026-02-01 22:25:32

Check Details
Exploring the efficacy of low-dose dacomitinib/dacomitinib (15 mg/day) in patients

2026-02-01 22:25:32

Check Details
Dacomitinib/dacomitinib combined with osimertinib

2026-02-01 22:25:32

Check Details
Category
相关知识